schizandrin b has been researched along with Diabetes Mellitus, Type 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M; Ma, R; Wang, X; Wu, L; Zhan, Y; Zhang, Y | 1 |
| Chen, L; Cui, W; Cui, X; Guo, T; Hu, H; Liu, N; Ma, W; Shang, J; Sun, Y; Wang, Z; Wei, X; Yan, W; Yi, X | 1 |
2 other study(ies) available for schizandrin b and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Body Weight; Cyclooctanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin Resistance; Lignans; Lipid Metabolism; Lipids; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Polycyclic Compounds; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2022 |
Schisandrin B, a potential GLP-1R agonist, exerts anti-diabetic effects by stimulating insulin secretion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Secretion; Mice; Molecular Docking Simulation; Peptides; Receptors, Glucagon | 2023 |